New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan

Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news